According to Zacks, “Selecta Biosciences, Inc. is a biopharmaceutical company which develops targeted immunotherapies and vaccines. Its product pipelineincludes gene therapy, food allergy, malaria; SEL-212, which is a therapeutic enzyme indicated for refractory gout; SEL-070, which is indicated for smoking cessation and relapse prevention; SEL-701, which is indicated for the treatment of human papillomavirus associated cancer and SEL-212 consists of SVP-Rapamycin co-administered with pegsiticase, its pegylated uricase. Selecta Biosciences, Inc. is based in Watertown, United States. “
Several other research analysts have also recently weighed in on SELB. Canaccord Genuity set a $40.00 price objective on shares of Mallinckrodt and gave the stock a buy rating in a research report on Monday, March 18th. Mizuho set a $88.00 price objective on shares of Gilead Sciences and gave the stock a buy rating in a research report on Friday, May 10th. Stifel Nicolaus restated a buy rating and issued a $7.00 price objective on shares of Selecta Biosciences in a research report on Friday, March 15th. Finally, ValuEngine cut shares of Zumiez from a hold rating to a sell rating in a research report on Tuesday, July 2nd. Two analysts have rated the stock with a sell rating, two have assigned a hold rating and five have issued a buy rating to the company. The company presently has a consensus rating of Hold and an average target price of $8.04.
Selecta Biosciences (NASDAQ:SELB) last posted its quarterly earnings data on Thursday, May 9th. The company reported ($0.31) earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.37) by $0.06. The company had revenue of $0.01 million during the quarter. On average, sell-side analysts predict that Selecta Biosciences will post -1.35 EPS for the current year.
Hedge funds have recently bought and sold shares of the stock. Barclays PLC increased its position in shares of Selecta Biosciences by 87.6% in the fourth quarter. Barclays PLC now owns 12,661 shares of the company’s stock worth $34,000 after purchasing an additional 5,911 shares during the last quarter. Rhumbline Advisers increased its position in shares of Selecta Biosciences by 50.3% in the fourth quarter. Rhumbline Advisers now owns 23,802 shares of the company’s stock worth $63,000 after purchasing an additional 7,965 shares during the last quarter. Two Sigma Advisers LP increased its position in shares of Selecta Biosciences by 18.3% in the fourth quarter. Two Sigma Advisers LP now owns 54,900 shares of the company’s stock worth $146,000 after purchasing an additional 8,500 shares during the last quarter. Deutsche Bank AG increased its position in shares of Selecta Biosciences by 251.6% in the fourth quarter. Deutsche Bank AG now owns 127,121 shares of the company’s stock worth $337,000 after purchasing an additional 90,970 shares during the last quarter. Finally, Geode Capital Management LLC increased its position in shares of Selecta Biosciences by 17.9% in the fourth quarter. Geode Capital Management LLC now owns 175,308 shares of the company’s stock worth $466,000 after purchasing an additional 26,568 shares during the last quarter. Institutional investors own 47.07% of the company’s stock.
About Selecta Biosciences
Selecta Biosciences, Inc, a clinical-stage biopharmaceutical company, researches and develops nanoparticle immunomodulatory drugs for the treatment and prevention of human diseases. Its proprietary pipeline includes therapeutic enzymes, gene therapies, and other products and product candidates affected by undesired immune responses.
Featured Story: Earnings Per Share (EPS)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Selecta Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Selecta Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.